Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist Financial

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price reduced by Truist Financial from $39.00 to $37.00 in a research note issued to investors on Wednesday morning, MarketBeat reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

AGIO has been the subject of a number of other reports. HC Wainwright raised their price target on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Citigroup boosted their price objective on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Bank of America raised their target price on Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Royal Bank Of Canada lifted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Finally, TD Cowen upgraded Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $41.50.

Agios Pharmaceuticals Trading Down 0.3%

Shares of AGIO stock opened at $31.81 on Wednesday. The stock has a market capitalization of $1.90 billion, a P/E ratio of -4.54 and a beta of 0.63. The firm’s 50 day moving average is $33.13 and its 200 day moving average is $32.61. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The business had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $26.39 million. On average, equities analysts predict that Agios Pharmaceuticals will post -5.83 EPS for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. This represents a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Agios Pharmaceuticals during the second quarter worth about $239,582,000. ADAR1 Capital Management LLC bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter valued at about $47,800,000. GW&K Investment Management LLC increased its position in shares of Agios Pharmaceuticals by 41.5% during the 4th quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock valued at $32,863,000 after purchasing an additional 354,359 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Agios Pharmaceuticals by 14.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,151,614 shares of the biopharmaceutical company’s stock valued at $38,940,000 after buying an additional 147,273 shares in the last quarter. Finally, Capital International Investors purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at about $19,159,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases. Based in Cambridge, Massachusetts, the company specializes in cellular metabolism and the development of therapies designed to address underlying disease biology rather than only treating symptoms.

Agios’ lead commercial product is Pyrukynd (mitapivat), an oral pyruvate kinase activator approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.